Motzer RJ, Penkov K, Haanen JBAG, et al. JAVELIN Renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). ESMO 2018, abstract LBA6_PR.
Geen verhoogd risico op andere kanker bij lynchsyndroom
sep 2018 | Gynaecologische oncologie, Maag-darm-leveroncologie